Á. Brea

发表

[Epidemiology of cerebrovascular disease in Spain].

Á. Brea, M. Laclaustra, E. Martorell, 2013, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clínica e Investigación en Arteriosclerosis (English Edition).

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine

R. Valls, R. Solà, Á. Brea, 2016, PloS one.

Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2020 .

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clínica e Investigación en Arteriosclerosis (English Edition).

Implantation of a biochemical and genetic screening programme for family hypercholesterolaemia. Collaboration between the clinical laboratory and lipid units: Design of the ARIAN Project

Á. Brea, P. Valdivielso, T. Arrobas Velilla, 2021, Clínica e Investigación en Arteriosclerosis (English Edition).

Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study

C. Brotons, A. Hernández-Mijares, Á. Brea, 2021, Journal of clinical medicine.

Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.

N. Plana, A. Bea, F. Civeira, 2021, Atherosclerosis.

Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry.

L. Pérez de Isla, L. Badimón, Á. Brea, 2020, Revista espanola de cardiologia.

Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study

Á. Brea, P. Valdivielso, T. Arrobas Velilla, 2022, Frontiers in Genetics.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, X. Pintó, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias

A. Hernández-Mijares, Á. Brea, X. Pintó, 2020, Clínica e Investigación en Arteriosclerosis (English Edition).

Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial

R. Valls, A. Pedret, R. Solà, 2014, PloS one.

Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe.

J. Banegas, Á. Brea, D. Zambón, 2014, European journal of public health.

Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)

G. Watts, L. Pérez de Isla, L. Badimón, 2017, Circulation.

Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.

N. Plana, F. Civeira, C. Lahoz, 2017, The American journal of cardiology.

Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia

E. Ros, F. Civeira, Á. Brea, 2007, Journal of Inherited Metabolic Disease.

Non-alcoholic fatty liver disease and cardiovascular risk.

Á. Brea, J. Puzo, 2013, International journal of cardiology.

Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study

Emilio Ros, E. Ros, Á. Brea, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease

Á. Brea, X. Pintó, P. González-Sántos, 2017 .

Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018 .

Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study.

G. Watts, J. López-Miranda, J. Alcalá-Díaz, 2015, International journal of cardiology.

Predicting Cardiovascular Events in Familial Hypercholesterolemia : The SAFEHEART Registry Running Title :

G. Watts, L. Badimón, R. Santos, 2017 .

Non-HDL cholesterol as a therapeutic goal.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Implantation of a biochemical and genetic screening programme for family hypercholesterolaemia. Collaboration between the clinical laboratory and lipid units: Design of the ARIAN Project.

Á. Brea, P. Valdivielso, T. Arrobas Velilla, 2021, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

A. Hernández-Mijares, Á. Brea, X. Pintó, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.